Enteric-coated tablet for treating colitis
By designing the structure and preparation process of enteric-coated tablets, the failure problem caused by the oxidation reaction of mesalazine preparations during the production process is solved, and the efficient release of mesalazine in the colon is achieved, which improves the therapeutic effect and product quality, and reduces the cost.
Patent Information
- Application Number
- CN202111220005.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-10-20
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2041-10-20
AI Technical Summary
The existing mesalamin preparations are prone to failure due to oxidation reaction during the production process, which affects the therapeutic effect. The granulation process is complex and cost-effective, making it difficult to ensure product quality and cost-effectiveness.
Using an enteric-coated tablet structure from the inside to the outside, including the sheet core, enteric-coated layer and coloring layer, it is prepared by dry granulation process, and using specific film-forming agents, anti-adhesive agents, plasticizers and lubricants to control the The tablets are insoluble in the stomach and small intestine, and quickly dissolve and release mesalazine in the colon, ensuring high local concentrations.
The release of mesalamin at the colon lesion site is achieved with high local concentration, improving the treatment effect, ensuring the stability and safety of product quality, and reducing the cost of the preparation, and the release curve is basically the same as the original drug.
Smart Images

Figure BDA0003312229860000011 
Figure BDA0003312229860000021 
Figure BDA0003312229860000041
Abstract
Description
Technical Field
[0001] The invention relates to the field of pharmaceutical preparations, and in particular to an enteric-coated tablet for treating colitis. Background Art
[0002] Mesalazine, chemical name: 2-hydroxy-5-amino-benzoic acid; molecular formula: C7H7NO3; molecular weight: 153.14; chemical structure is as follows:
[0003]
[0004] Mesalazine is an aminosalicylate used to treat inflammatory bowel disease (IBD). IBD manifests itself in various forms, the most common forms being Crohn's disease (CD) and ulcerative colitis (UC). CD is a chronic transmural enteritis that can affect the entire gastrointestinal tract, usually in a non-continuous pattern. The initial site of CD is most often the lower ileum, from which the inflammation usually spreads to the proximal portion of the small intestine, however, the colon is often also involved. UC is a chronic inflammatory bowel disease that affects only the colon and shows a continuous distribution in the gastrointestinal mucosa. In most patients, inflammation is primarily distal to the colon and rectum, often with proximal spread. In the most severe cases, the entire colon is affected ("pancolitis").
[0005] Mesalazine has an anti-inflammatory effect in the colon and large intestine, and is mainly used for the acute onset and remission of mild and moderate ulcerative colitis, and long-term maintenance treatment of ulcerative colitis. Clinical trials have shown that mesalazine can eliminate inflammation and relieve basic clinical symptoms in the treatment of ulcerative colitis; long-term use can maintain the remission of clinical symptoms; reduce the incidence of side effects; and prevent the occurrence of complications. It is the first-line drug for ulcerative colitis. However, due to the three active reactive groups of amino, hydroxyl and carboxyl in its structure, it can undergo a variety of reactions. It is easily oxidized and ineffective during the production process, thus affecting the treatment effect. Therefore, it is necessary to control the temperature and humidity to reduce the occurrence of chemical reactions, protect the content of active ingredients, and reduce the production of related substances.
[0006] Chinese patent document CN1355694A discloses a mesalazine controlled-release oral pharmaceutical composition, comprising: a) an internal lipophilic matrix, composed of a substance with a melting point below 90°C, wherein at least part of the active ingredient is contained; b) an external hydrophilic matrix, wherein the lipophilic matrix is dispersed; c) other optional excipients. In this process, a lipophilic matrix and mesalazine are granulated to prepare tablets. Since the lipophilic matrix used is composed of a substance with a melting point below 90°C, special production equipment is required in the granulation process, which increases the complexity of the process.
[0007] Chinese patent document CN101721385A discloses a mesalazine oral colon-targeted sustained-release pharmaceutical composition, comprising: a) a sustained-release tablet core containing mesalazine or its pharmaceutical salt or its solvate and a hydrophilic matrix, wherein the mesalazine or its pharmaceutical salt is dispersed in the hydrophilic matrix; b) a coating containing an acid-resistant material is coated on the outside of the tablet core; c) the composition releases less than 20% in 1 hour, 30-60% in 4 hours, and more than 70% in 8 hours in simulated intestinal fluid at pH 7.2. The composition has a simple manufacturing process and low cost, and slowly releases mesalazine in the small intestine and colon to achieve once-daily colon-targeted administration and local treatment effects. The patent document process uses aqueous solvent granulation, and the drying temperature and drying time must be strictly controlled during the drying process. If you are not careful, the related substances are likely to increase, which brings safety hazards to product quality.
[0008] Therefore, there is still a demand for mesalazine preparations with good product quality and low cost. Summary of the invention
[0009] In view of the deficiencies of the prior art, the object of the present invention is to provide an enteric-coated tablet for treating colitis, which can prevent dissolution in the front part of the digestive tract such as the stomach and small intestine, and quickly dissolve and release in the colon, thereby ensuring that it has a high local concentration in the lesion site of the colon and exerts a better therapeutic effect.
[0010] In order to achieve the above-mentioned invention object, the technical solution adopted by the present invention is as follows:
[0011] An enteric-coated tablet for treating colitis, comprising, from inside to outside, a tablet core, an enteric-coated layer and a coloring layer;
[0012] The core comprises:
[0013]
[0014] The enteric layer comprises:
[0015] Film-forming agent 80-150 parts by weight
[0016] Anti-adhesive agent 5-20 parts by weight
[0017] Plasticizer 5-20 parts by weight
[0018] The filler is one or more of lactose, starch, microcrystalline cellulose and mannitol;
[0019] The pH regulator is one or more of calcium carbonate, sodium carbonate, glycine, and a glycine-sodium carbonate complex;
[0020] The disintegrant is one or more of low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, and cross-linked polyvinylpyrrolidone;
[0021] The binder is one or more of hydroxypropyl cellulose, povidone, and hydroxypropyl methyl cellulose;
[0022] The glidant is one or more of colloidal silicon dioxide, talcum powder, and micro-powdered silica gel;
[0023] The lubricant is one or more of magnesium stearate, calcium stearate, and sodium stearyl fumarate;
[0024] The film-forming agent is one or more of: methacrylic acid-methyl methacrylate (1:1) copolymer (Eudra L100), methacrylic acid-methyl methacrylate (1:2) copolymer (Eudra S100), methacrylic acid-methacrylic acid (1:1) copolymer (Eudra L100-55);
[0025] The anti-adhesive agent is one or more of talc, glyceryl monostearate, and micro-powder silica gel;
[0026] The plasticizer is one or more of polyethylene glycol, triethyl citrate and diethyl phthalate.
[0027] Preferably,
[0028] The filler is: microcrystalline cellulose;
[0029] The pH regulator is: glycine and sodium carbonate (weight ratio is 1:11), or a glycine-sodium carbonate complex;
[0030] The disintegrant is: cross-linked carboxymethyl cellulose sodium;
[0031] The adhesive is: povidone;
[0032] The glidant is: colloidal silicon dioxide;
[0033] The lubricant is: magnesium stearate;
[0034] The film-forming agent is: methacrylic acid-methyl methacrylate (1:1) copolymer (Ultrac L100);
[0035] The anti-adhesive agent is: talcum powder;
[0036] The plasticizer is polyethylene glycol.
[0037] Preferably,
[0038] The core comprises:
[0039]
[0040]
[0041] The enteric layer comprises:
[0042] Film-forming agent 90-130 parts by weight
[0043] Anti-adhesive agent 5-20 parts by weight
[0044] Plasticizer 5-20 parts by weight
[0045] More preferably,
[0046] The core comprises:
[0047]
[0048] The enteric layer comprises:
[0049] Film-forming agent 90-120 parts by weight
[0050] Anti-adhesive agent 5-15 parts by weight
[0051] Plasticizer 5-15 parts by weight
[0052] Preferably, the weight of the enteric layer is 15% to 17% of the weight of the tablet core.
[0053] Preferably, in the coloring layer, the coating material is Opadry.
[0054] Preferably, the weight of the colored layer is 2% to 4% of the total weight of the core tablet and the enteric layer.
[0055] Preferably, the tablet core is made into granules by a dry granulation process and then compressed into tablets.
[0056] In the dry granulation, the roller pressure is controlled at about 10 bar to 70 bar, the roller speed is controlled at about 6 rpm to 20 rpm, the granulation speed is controlled at about 100 rpm to 150 rpm, and the sieve aperture is controlled at 0.6 mm to 2.0 mm; the hardness of the tablet core is controlled at about 80 N to 150 N.
[0057] Further preferably, in the dry granulation, the roller pressure is controlled at about 10 bar to 50 bar, the roller speed is controlled at about 6 rpm to 15 rpm, the granulation speed is controlled at about 110 rpm to 140 rpm, and the sieve aperture is controlled at 0.8 mm to 1.5 mm.
[0058] More preferably, in the dry granulation, the roller pressure is controlled at about 10 bar to 40 bar, the roller speed is controlled at about 6 rpm to 15 rpm, the granulation speed is controlled at about 120 rpm to 130 rpm, and the sieve aperture is controlled at 1.0 mm to 1.5 mm.
[0059] Preferably, the hardness of the core is controlled within a range of about 90N to 140N; more preferably, the hardness of the core is controlled within a range of about 100N to 130N.
[0060] In a specific embodiment, in the dry granulation, the roller pressure is controlled at about 30 bar, the roller speed is controlled at about 10 rpm, the granulation speed is controlled at about 130 rpm, and the sieve aperture is controlled at 1.0 mm.
[0061] In a specific embodiment, the hardness of the core is controlled at about 120N.
[0062] The tablet core comprises: 500 parts by weight of mesalamine, 65 parts by weight of microcrystalline cellulose, 20 parts by weight of povidone, 15 parts by weight of cross-linked carboxymethyl cellulose sodium, 10 parts by weight of glycine, 110 parts by weight of sodium carbonate, 10 parts by weight of colloidal silicon dioxide, and 10 parts by weight of magnesium stearate;
[0063] The enteric layer comprises: 100 parts by weight of methacrylic acid-methyl methacrylate (1:1) copolymer (Eutrac L100), 9.2 parts by weight of talc, and 9.2 parts by weight of polyethylene glycol.
[0064] In a specific embodiment, the enteric-coated tablets for treating colitis of the present invention, each unit preparation comprises:
[0065]
[0066] According to the enteric-coated tablets for treating colitis of the present invention, under the dissolution conditions of 0.1N hydrochloric acid and paddle method at 100 rpm, the tablets do not crack or disintegrate for 2 hours, and then under the dissolution conditions of simulated intestinal fluid at pH 6.8 and paddle method at 100 rpm, the release in 15 minutes is less than 5%, and the release in 60 minutes is more than 80%.
[0067] Preferably, the method for preparing the enteric-coated tablets for treating colitis of the present invention comprises the following steps:
[0068] (1) Mixing mesalazine, a filler, a pH adjuster, a disintegrant, a binder, and a glidant uniformly, and then adding a portion of a lubricant and mixing uniformly to obtain a premixed powder;
[0069] (2) setting the roller speed of the dry granulator to 10 rpm, the roller pressure to 30 bar, the granulation speed to 130 rpm, and the screen aperture to 1.0 mm, dry granulating the premixed powder to obtain granules;
[0070] (3) mixing the obtained granules with the remaining lubricant uniformly, and pressing the tablets to obtain a tablet hardness of 120N to obtain a tablet core;
[0071] (4) The obtained tablet core is coated with an enteric layer and a coloring layer.
[0072] The enteric-coated tablets for treating colitis provided by the present invention have stable quality, ensure the safety and effectiveness of medication, and have a release curve that is basically consistent with the original drug. Under the dissolution conditions of 0.1N hydrochloric acid and paddle method at 100rpm, the tablets do not crack or disintegrate for 2 hours, and then under the dissolution conditions of simulated intestinal fluid at pH 6.8 and paddle method at 100rpm, the release rate is less than 5% in 15 minutes and more than 80% in 60 minutes; it can prevent dissolution in the front part of the digestive tract such as the stomach and small intestine, and quickly dissolve and release in the colon, thereby ensuring that it has a high local concentration in the colon lesion site and exerts a better therapeutic effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0073] Figure 1 The dissolution curves of the enteric-coated tablets for treating colitis prepared by prescription 1 in Example 1 and the original drug. The broken line A is the dissolution curve of the enteric-coated tablets for treating colitis of the present invention, and the broken line B is the dissolution curve of the original drug;
[0074] Figure 2 The dissolution curves of the enteric-coated tablets for treating colitis and the original drug prepared in Example 2. The broken line A is the dissolution curve of the enteric-coated tablets for treating colitis of the present invention, and the broken line B is the dissolution curve of the original drug;
[0075] Figure 3 The dissolution curves of the enteric-coated tablets for treating colitis and the original drug prepared in Example 3 are shown in FIG. The broken line A is the dissolution curve of the enteric-coated tablets for treating colitis of the present invention, and the broken line B is the dissolution curve of the original drug. DETAILED DESCRIPTION
[0076] In order to better understand and illustrate the present invention, an exemplary description is given below on the enteric-coated tablets for treating colitis provided by the present invention, but it should not be construed as limiting the content of the invention.
[0077] The equipment and instruments used in the following examples mainly include: FZB-150 crushing and granulating machine; LGS-120 dry granulator; BSL-25 mixer; ZP-10A tablet press; YD-35 tablet hardness tester; BGB-5F high-efficiency coating machine; RC806 dissolution apparatus; Agilent 1260 high-performance liquid chromatograph.
[0078] The glycine-sodium carbonate complex (monosodium glycine carbonate, CAS registration number: 50610-34-9): the manufacturer is FINAR Company of India; the domestic agent is Luofu Pharmaceutical: batch number: 307103517LS.
[0079] Example 1
[0080] (1) The prescription is shown in Table 1:
[0081] Table 1 Prescription of Mesalazine Enteric-coated Tablets
[0082]
[0083] (2) Preparation method
[0084] Tablet preparation:
[0085] According to the prescription in Table 1, microcrystalline cellulose, povidone, colloidal silicon dioxide, mesalazine, glycine, anhydrous sodium carbonate and cross-linked sodium carboxymethyl cellulose are mixed evenly, and then part of the lubricant is added and mixed evenly to obtain a premixed powder;
[0086] The roller speed of the dry granulator was set to 10 rpm, the roller pressure was set to 30 bar, the granulation speed was set to 130 rpm, and the sieve aperture was set to 1.0 mm, and the premixed powder was dry granulated to obtain granules;
[0087] The obtained granules are mixed evenly with the remaining lubricant, and tablets are pressed, and the tablet hardness is 120N to obtain a tablet core;
[0088] Enteric coating:
[0089] Slowly add Eudragit L100 into 95% ethanol while stirring until Eudragit L100 is completely dissolved, then add talcum powder and polyethylene glycol, mix well and set aside.
[0090] Place the tablet cores in a coating pan, preheat to a predetermined temperature, and start spray coating. During the coating process, adjust the air outlet temperature to 25°C to 35°C, the coating pan speed to 6 to 10 r / min, the atomization pressure to 0.10 to 0.20 MPa, and the spray speed to 30 to 60 r / min.
[0091] Coloring coating:
[0092] Disperse Opadry evenly in purified water under stirring and set aside.
[0093] Place the above-mentioned coated tablets in a coating pan, preheat to a predetermined temperature, and then start spray coating. During the coating process, adjust the air outlet temperature to 30°C to 50°C, the coating pan speed to 6 to 10 r / min, the atomization pressure to 0.10 to 0.20 MPa, and the spray speed to 15 to 30 r / min.
[0094] Example 2
[0095] (1) The prescription is shown in Table 2:
[0096] Table 2 Prescription of Mesalazine Enteric-coated Tablets
[0097]
[0098]
[0099] (2) Preparation method
[0100] Tablet preparation:
[0101] The microcrystalline cellulose, povidone, colloidal silicon dioxide, mesalazine, glycine-sodium carbonate complex and cross-linked sodium carboxymethyl cellulose are mixed evenly, and then part of the lubricant is added and mixed evenly to obtain a premixed powder;
[0102] The roller speed of the dry granulator was set to 10 rpm, the roller pressure was set to 30 bar, the granulation speed was set to 130 rpm, and the sieve aperture was set to 1.0 mm, and the premixed powder was dry granulated to obtain granules;
[0103] The obtained granules are mixed evenly with the remaining lubricant, and tablets are pressed, and the tablet hardness is 120N to obtain a tablet core;
[0104] Enteric coating:
[0105] Slowly add Eudragit L100 into 95% ethanol while stirring until Eudragit L100 is completely dissolved, then add talcum powder and polyethylene glycol, mix well and set aside.
[0106] Place the tablet cores in a coating pan, preheat to a predetermined temperature, and start spray coating. During the coating process, adjust the air outlet temperature to 25°C to 35°C, the coating pan speed to 6 to 10 r / min, the atomization pressure to 0.10 to 0.20 MPa, and the spray speed to 30 to 60 r / min.
[0107] Coloring coating:
[0108] Disperse Opadry evenly in purified water under stirring and set aside.
[0109] Place the above-mentioned coated tablets in a coating pan, preheat to a predetermined temperature, and then start spray coating. During the coating process, adjust the air outlet temperature to 30°C to 50°C, the coating pan speed to 6 to 10 r / min, the atomization pressure to 0.10 to 0.20 MPa, and the spray speed to 15 to 30 r / min.
[0110] Example 3
[0111] (1) The prescription is shown in Table 3:
[0112] Table 3 Prescription of Mesalazine Enteric-coated Tablets
[0113]
[0114]
[0115] (2) Preparation method
[0116] Tablet preparation:
[0117] The microcrystalline cellulose, povidone, colloidal silicon dioxide, mesalazine, glycine-sodium carbonate complex and cross-linked sodium carboxymethyl cellulose are mixed evenly, and then part of the lubricant is added and mixed evenly to obtain a premixed powder;
[0118] The roller speed of the dry granulator was set to 10 rpm, the roller pressure was set to 30 bar, the granulation speed was set to 130 rpm, and the sieve aperture was set to 1.0 mm, and the premixed powder was dry granulated to obtain granules;
[0119] The obtained granules are mixed evenly with the remaining lubricant, and tablets are pressed, and the tablet hardness is 120N to obtain a tablet core;
[0120] Enteric coating:
[0121] Slowly add Eudragit L100 into 95% ethanol while stirring until Eudragit L100 is completely dissolved, then add talcum powder and polyethylene glycol, mix well and set aside.
[0122] Place the tablet cores in a coating pan, preheat to a predetermined temperature, and start spray coating. During the coating process, adjust the air outlet temperature to 25°C to 35°C, the coating pan speed to 6 to 10 r / min, the atomization pressure to 0.10 to 0.20 MPa, and the spray speed to 30 to 60 r / min.
[0123] Coloring coating:
[0124] Disperse Opadry evenly in purified water under stirring and set aside.
[0125] Place the above-mentioned coated tablets in a coating pan, preheat to a predetermined temperature, and then start spray coating. During the coating process, adjust the air outlet temperature to 30°C to 50°C, the coating pan speed to 6 to 10 r / min, the atomization pressure to 0.10 to 0.20 MPa, and the spray speed to 15 to 30 r / min.
[0126] Example 4 Acid resistance test
[0127] The mesalazine enteric-coated tablets of prescriptions 1 to 5 in Example 1 were mixed with the commercially available original drug Acid resistance test (phenomenon or membrane breaking time in different media) was performed. The results are as follows:
[0128]
[0129]
[0130] The results showed that when the acid resistance was tested in 0.1N hydrochloric acid and pH 6.8 phosphate buffer, the acid resistance test results of Prescriptions 1 to 5 were similar to those of the original drug.
[0131] Example 5 Dissolution Experiment
[0132] Method: Imported registered standard (JX20080236), paddle method 100rpm.
[0133] Dissolution medium: 0.1N hydrochloric acid / pH 6.8 phosphate buffer, 1000ml.
[0134] Test samples: enteric-coated tablets for treating colitis prepared in Example 1, Example 2 and Example 3 and the original drug (manufactured by Losan Pharma GmbH, batch number L20039A).
[0135] Test results: see Figure 1 to Figure 3 . Figure 1 It is a dissolution curve diagram of the enteric-coated tablets for treating colitis prepared according to Prescription 1 of Example 1 and the original drug, wherein broken line A is the dissolution curve of the enteric-coated tablets for treating colitis of the present invention, and broken line B is the dissolution curve of the original drug. Figure 2 It is a dissolution curve diagram of the enteric-coated tablets for treating colitis prepared in Example 2 and the original drug, wherein the broken line A is the dissolution curve of the enteric-coated tablets for treating colitis of the present invention, and the broken line B is the dissolution curve of the original drug. Figure 3 It is a dissolution curve diagram of the enteric-coated tablets for treating colitis prepared in Example 3 and the original drug, wherein the broken line A is the dissolution curve of the enteric-coated tablets for treating colitis of the present invention, and the broken line B is the dissolution curve of the original drug.
[0136] The results showed that the release curve trends of the enteric-coated tablets for treating colitis prepared in Example 1, Example 2 and Example 3 in 0.1N hydrochloric acid + pH 6.8 phosphate buffer were similar to those of the original drug. The release curve trends are basically the same, that is, under the dissolution conditions of 0.1N hydrochloric acid and paddle method at 100rpm, the tablets did not crack or disintegrate for 2 hours, and then under the dissolution conditions of simulated intestinal fluid of pH 6.8 and paddle method at 100rpm, the release in 15min was less than 5%, and the release in 60min was more than 80%. The enteric-coated tablets for treating colitis prepared in Example 1 Prescription 1, Example 2 and Example 3 can prevent dissolution in the front part of the digestive tract such as the stomach and small intestine, and are rapidly dissolved and released in the colon, thereby ensuring that it has a high local concentration in the colon lesion site and exerts a better therapeutic effect.
[0137] Example 5 Stability Test
[0138] Conditions: Temperature: 50℃±2℃; Humidity: 75%RH±5%RH; Observation time: 4 weeks, sampling was performed at 0 o'clock, 2 weeks, and 4 weeks to observe its stability. The results are as follows:
[0139]
[0140] The results showed that the enteric-coated tablets for treating colitis prepared in Example 1, Prescription 1, Example 2 and Example 3 were placed under 50°C / 75%RH for 2 weeks and 4 weeks, and the content of related substances did not show significant increase.
[0141] Based on the above description of the invention, those skilled in the art can fully apply the present invention, and all modifications based on the same principles or similar principles should be considered to be included in the scope of the present invention.
Claims
1. An enteric-coated tablet for treating colitis, comprising, from inside to outside: A tablet core, an enteric layer and a coloring layer; the tablet core comprises: The enteric layer comprises: Film-forming agent 80-150 parts by weight Anti-adhesive agent 5-20 parts by weight Plasticizer 5-20 parts by weight The filler is: microcrystalline cellulose; The pH regulator is: glycine and sodium carbonate in a weight ratio of 1:11, or a glycine-sodium carbonate complex; the disintegrant is: cross-linked sodium carboxymethyl cellulose; The adhesive is: povidone; The glidant is: colloidal silicon dioxide; The lubricant is: magnesium stearate; The film-forming agent is: methacrylic acid-methyl methacrylate 1:1 copolymer; The anti-adhesive agent is: talcum powder; The plasticizer is: polyethylene glycol; In the coloring layer, the coating material is Opadry; The tablet core is made into granules by dry granulation process and then compressed into tablets.
2. The enteric-coated tablet according to claim 1, characterized in that The core comprises: The enteric layer comprises: Film-forming agent 90-130 parts by weight Anti-adhesive agent 5-20 parts by weight Plasticizer 5-20 parts by weight.
3. The enteric-coated tablet according to claim 1, characterized in that The core comprises: The enteric layer comprises: Film-forming agent 90-120 parts by weight Anti-adhesive agent 5-15 parts by weight Plasticizer 5-15 parts by weight.
4. The enteric-coated tablet according to claim 1, characterized in that: The weight of the enteric layer is 15% to 17% of the weight of the tablet core.
5. The enteric-coated tablet according to claim 1, characterized in that: The weight of the colored layer is 2% to 4% of the total weight of the tablet core and the enteric layer.
6. The enteric-coated tablet according to claim 1, characterized in that: The tablet core comprises: 500 parts by weight of mesalamine, 65 parts by weight of microcrystalline cellulose, 20 parts by weight of povidone, 15 parts by weight of cross-linked carboxymethyl cellulose sodium, 10 parts by weight of glycine, 110 parts by weight of sodium carbonate, 10 parts by weight of colloidal silicon dioxide, and 10 parts by weight of magnesium stearate; The enteric layer comprises: 100 parts by weight of methacrylic acid-methyl methacrylate 1:1 copolymer, 9.2 parts by weight of talc, and 9.2 parts by weight of polyethylene glycol.
7. The enteric-coated tablet according to claim 1, characterized in that: The enteric-coated tablets, under the dissolution conditions of 0.1N hydrochloric acid and paddle method at 100 rpm, showed no cracks or disintegration in 2 hours, and then under the dissolution conditions of simulated intestinal fluid at pH 6.8 and paddle method at 100 rpm, the release in 15 minutes was less than 5%, and the release in 60 minutes was more than 80%.
Citation Information
Patent Citations
Mesalazine oral controlled release medicine composition
CN101721385A
Measalazine controlled redease oral pharmaceutical compositions
CN1355694A
Mesalazine tablet having improved dissolution
CN103108629A
